Methadone Versus Morphine for Cancer-Related Pain

NCT ID: NCT00573937

Last Updated: 2016-02-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-08-31
• Study Completion Date: 2009-04-30

Brief Summary

The purpose of this study is to compare methadone with morphine in the management of moderate to severe cancer pain.

Detailed Description

Treatment of cancer pain is based on the World Health Organization (WHO) step ladder approach to the use of analgesic drugs. Medication potency increases at each step of the WHO ladder, from nonopioid (step 1; e.g., aspirin and nonsteroidal anti-inflammatory drugs) through weak opioids (step 2; e.g. codeine) plus a nonopioid to strong opioids (step 3; e.g., morphine) plus a nonopioid analgesic. Morphine is considered the gold standard for the treatment of moderate to severe pain, but this is based on level C criteria. Research has discovered that methadone is a potent opioid that operates at several levels which are important for pain control. The primary aim is to compare morphine versus methadone as a first-line analgesic in patients with moderate to severe cancer pain. Patients will be randomized to receive either oral slow-release morphine (15 mg) every 8 hours and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain or oral methadone 2.5 mg every 8 hours and methadone 2.5 mg every 4 hours as needed for breakthrough pain. Our hypothesis is that methadone will provide equivalent pain control efficacy after 4 weeks of therapy. We postulate that methadone will be as preferable as morphine as an analgesic. We will compare the two drugs via adverse effects and compare stability of analgesia via comparison of the number of breakthrough pain episodes. The study will attempt to establish equivalency of methadone as a first-line analgesic for moderate to severe cancer pain.

Conditions

Neoplasms; Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Methadone

Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.

Group Type: ACTIVE_COMPARATOR

Methadone

Intervention Type: DRUG

Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.

Morphine

Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.

Group Type: ACTIVE_COMPARATOR

Morphine

Intervention Type: DRUG

Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.

Interventions

Methadone

Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.

Intervention Type: DRUG

Morphine

Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.

Intervention Type: DRUG

Other Intervention Names

Methadone Hydrochloride; Methadose; Dolophine Hydrochloride; Morphine Sulfate

Eligibility Criteria

Inclusion Criteria

• Must have a telephone
• Age: patient must be 18 years or older and less than 70 years of age
• Life expectancy of 3 months or greater
• No prior use of step-3 opioids (step 2 opioids are allowed)
• Provision of informed consent
• Score of 26 or greater on Mini-Mental Status Exam (MMSE) (to be done by investigator if there is question about mental status)
• Nonmalignant pain will be excluded; however, if the patient has both malignant and nonmalignant pain, entry into the trial will be determined by the predominant site of pain
• Moderate to severe cancer related pain that requires the use of step-3 opioids
• Normal renal function
• There will be no exclusionary criteria based on Karnofsky score
• Must live no more than 1 hour away from clinic
• Patient must have pain severity of 5-7/10 on a 0-10 pain scale

Exclusion Criteria

• Nursing home patients
• Obvious cognitive dysfunction
• Intractable nausea or vomiting
• A true allergy or intolerance to opioids
• Unstable renal function
• Undergoing therapeutic procedures likely to influence pain during the study period
• Gastrointestinal pathology or surgery that influences absorption of morphine or methadone
• Must not have had treatment with radiotherapy, chemotherapy or radionuclides in the last 30 days
• History of drug seeking behavior
• Respiratory compromise
• Treatment with bisphosphonates within the last month
• Use of MAO inhibitors
• Drugs that interfere with CYP34A or CYP2D6
• Drugs that interfere with morphine metabolism
• Retroviral therapies
• Active radiation or antineoplastic therapies
• Hepatic dysfunction
• As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
• Study will exclude women who are pregnant and/or nursing
• Women who are of child bearing potential must have a negative urine pregnancy test
• Patients with a recent substance abuse history will be excluded
• Patients with major depression will be excluded

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Donald W. Northfelt, M.D.

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Donald Northfelt, M.D.

Role: STUDY_CHAIR

Mayo Clinic

Locations

Mayo Clinic Arizona

Scottsdale, Arizona, United States

Countries

United States

Other Identifiers

07-003051

Identifier Type: -

Identifier Source: org_study_id